Smith, Rona M.
Cooper, Daniel J.
Doffinger, Rainer
Stacey, Hannah
Al-Mohammad, Abdulrahman
Goodfellow, Ian
Baker, Stephen
Lear, Sara
Hosmilo, Myra
Pritchard, Nicholas
Torpey, Nicholas
Jayne, David
Yiu, Vivien
Chalisey, Anil
Lee, Jacinta
Vilnar, Enric
Cheung, Chee Kay
Jones, Rachel B.
Article History
Received: 24 December 2021
Accepted: 11 April 2022
First Online: 31 May 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations.All experimental protocols were approved: 1. The prospective observational cohort study (ethics reference: 20/EM/0180) by East Midlands - Leicester Central Research Ethics Committee. 2. Healthy controls (ethics reference: 17/EE/0025) by East of England - Cambridge Central Research Ethics Committee.Informed consent was obtained from all subjects.
: Not applicable.
: RM Smith has received research grants from Union Therapeutics, GlaxoSmithKline, LifeArc, Kidney Research UK and Addenbrooke’s Charitable Trust. IG has received charitable research grants from the Wellcome Trust and UKRI. SL has received a charitable research grant from Addenbrookes Charitable Trust. DRW Jayne’s disclosures of commercial conflicts for companies are: Astra-Zeneca, Aurinia, BMS, Boehringer-Ingelheim, GSK, Janssen, Novartis, Roche/Genentech, Takeda & Vifor. CK Cheung has received a research grant from GlaxoSmithKline and advisory board fees from Vifor Pharma. RB Jones has received research grants from GlaxoSmithKline and Roche and advisory board fees from Vifor Pharma and GlaxoSmithKline. Rest of the authors have no Conflict of interest to declare.The results presented in this paper have not been published previously in whole or part, except in abstract format.